Starling Oncology, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Starling Oncology, Inc. (DFPH) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$867.48 thousand for the 9-month period ending 2021-09-30, per its 10-Q/A filed 2021-12-14.
Discontinued › Income Statement
us-gaap:ProfitLoss · last filed 2021-12-14
- Starling Oncology, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2021-09-30 was -$432.03K.
- Starling Oncology, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2021-06-30 was -$6.12M.
- Starling Oncology, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2021-03-31 was $5.69M.
- Starling Oncology, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2020-12-31 was -$2.53M.
- Starling Oncology, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2020 was -$8.34M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 2 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2021-09-30 | -$432.03K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2021-12-14 | -$6.55M derived: sum of 2 quarters · filed 2021-12-14 | -$867.48K 10-Q/A · filed 2021-12-14 | -$3.40M derived: sum of 4 quarters · filed 2021-12-14 | |||||
| 2021-06-30 | -$6.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$435.44K 10-Q · filed 2021-08-16 | -$2.96M derived: sum of 3 quarters · filed 2021-12-14 | -$5.38M derived: sum of 4 quarters · filed 2021-12-14 | |||||
| 2021-03-31 | $5.69M 10-Q · filed 2021-05-28 | $3.16M derived: sum of 2 quarters · filed 2021-12-14 | $740.97K derived: sum of 3 quarters · filed 2021-12-14 | -$1.88M derived: sum of 4 quarters · filed 2021-12-14 | |||||
| 2020-12-31 | -$2.53M derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2021-12-14 | -$4.94M derived: sum of 2 quarters · filed 2021-12-14 | -$7.56M derived: sum of 3 quarters · filed 2021-12-14 | -$8.34M 10-K/A · filed 2021-12-14 | -$441.15K 10-K · filed 2021-03-30 | ||||
| 2020-09-30 | -$2.42M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2021-12-14 | -$5.04M derived: sum of 2 quarters · filed 2021-12-14 | -$5.81M 10-Q/A · filed 2021-12-14 | -$298.48K 10-Q · filed 2020-11-13 | |||||
| 2020-06-30 | -$2.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$3.40M 10-Q · filed 2021-08-16 | -$160.82K 10-Q · filed 2020-08-13 | ||||||
| 2020-03-31 | -$776.84K 10-Q · filed 2021-05-28 | -$45.09K 10-Q · filed 2020-05-08 | |||||||
| 2019-12-31 | -$2.30K 10-K/A · filed 2021-12-14 |